Alzheimer's disease (AD) is the most frequent and multifactorial form of dementia, characterised by multiple cognitive impairments and personality changes. Different methods including chemicals have been used to induce AD-like symptoms in rodent in order to screen many therapeutic drugs for a variety of cognitive dysfunctions. Articles from reliable databases such as Google Scholar, Science Direct, PubMed, Scopus, and Ovid were searched and retrieved with the following descriptors: 'Alzheimer's Disease' , Cognitive impairments' , Neurotoxins that induce AD' , Alzheimerogenic chemicals' , excitotoxins' , Amyloid beta' , neurofibrillary tangles. A number of chemicals have been studied to develop an animal model of AD on the basis of their mechanism of action for cognitive dysfunctions. Some of such chemicals are Heavy metals, Scopolamine, Ethanol, Colchicine, Streptozotocin, Lipopolysaccharide, and Okadaic acid among others, with a view to understanding the pathogenesis of this devastating disease. The purpose of this review is to put forward some AD pathophysiology including AD causative theories and also highlight some Alzheimerogenic chemicals for the purpose of enriching our existing knowledge. It is worth mentioning that not all the biochemical, histopathological, cognitive and behavioural abnormalities can be recapitulated. Nonetheless, experimental models of AD produced by chemicals offer insights to unravelling the pathogenesis of the disease.
INTRODUCTION
As the aging population is increasing, the rate of age-associated diseases among older adults has become a serious health concern worldwide 1 . It is wellestablished that these age-related diseases cause progressive and irreversible loss of neurons and subsequently lead to dementia. One of such age-related disorders is Alzheimer's disease (AD). AD, a neurodegenerative disease, is one of the most common and multifactorial forms of dementia characterized by multiple cognitive impairments, personality changes, and abnormal behavior 2 . The key pathological emblems observed in AD brain tissues are amyloid beta (Aβ ) peptide and hyperphosphorylated tau (p-tau) protein, although the exact mechanisms which cause these alterations are yet to be uncovered 3 . The formation of Aβ is due to the aggregation of extracellular senile plaques (SP), while neurofibrillary tangles (NFTs) are caused by abnormal deposits of p-tau proteins 3 . Furthermore, mitochondrial dysfunction, synaptic damage, inflammatory responses, defective neurotransmissions, hormonal alterations and abnormali-ties in the cell cycle are all linked with AD 4-6 . The remarkable risk factors linked with the progression of AD are old age, as well as multiple genetic and environmental factors. Although the etiology of AD remains unclear, multiple findings have revealed that oxidative stress is an early characteristic of the AD pathological process and also involved in the formation of Aβ and NFTs 7 . Thus, several attempts are ongoing in order to establish anti-AD drugs that could target specific pathogenesis, but these have not garnered much success. On the other hand, animal models have been used to trigger pathological changes similar to the human form of AD and to identify the pathogenesis, especially during the pre-symptomatic stage 8 . There is a dearth of knowledge with respect to chemically-induced AD models. Hence, this review is aimed at exploring some of the chemicals that are used for the induction of AD-like pathologies and behavioral deficits. much interest was placed on AD research 9 . The findings that have emerged have unraveled and demonstrated, importantly, that the effects of AD commence a long time before its symptoms manifest 10 . Several lines of evidence have revealed that AD is a prevailing root of dementia and a significant source of death in the world 11, 12 . Since its discovery, AD has received substantial attention among the types of dementias that are of global health concern, over the years, due to its debilitating nature. To date, the precise etiology of AD remains to be elucidated, as well as questions such as why the disorder and its symptoms advance so quickly in some people (but is delayed in others), and how the disorder could be more effectively managed or treated 10 .
CHARACTERISTICS AND SYMPTOMS OF AD
AD is characterized by loss of memory, mood swings, problems with attention and orientation, and difficulties in carrying out daily activities. The two main pathological hallmarks of AD are aggregations of amyloid plaques (extracellular) formed by Aβ and NFTs (intracellular), produced by the hyperphosphorylation of tau protein 3 . These alterations are ultimately followed by severe damage and loss of neurons in the brain regions concerned with memory and learning 10 . AD is distinguished at the cellular level by mitochondrial dysfunction, oxidative stress 13 , metal imbalance, inflammation, and apoptosis, among other hallmarks 14, 15 . Furthermore, several symptoms are observed in individuals living with AD which changes over a period of time. Of the symptoms reported, loss of memory in recalling recent conversations are some of the early clinical manifestations; as well, depression and apathy have been identified in AD. Additionally, other symptoms that appear later in life as the disease progresses include amnesia 16 , disorientation, impaired communication, confusion, poor judgement, difficulty in swallowing, speaking, and walking 10 . These important changes seen in AD patients reflect the severity of neuronal loss in different regions of the brain. There are three stages in AD: early, moderate and severe-through which the symptoms of the disease progress and differ from individual to individual. During the early stage of AD, patients can carry out basic things independently with little assistance for some activities; these activities include driving, walking, and other hobbies that can still be done by the patients 10, 17 . However, during the moderate stage of AD, patients may be unable to carry out routine activities, may become disoriented, and even develop personality disorders and behavioral changes (such as agitation and suspiciousness). Once it reaches the severe stage of AD, the patients become dependent on people in doing daily activities, such as eating, dressing, and bathing, among other activities 17 .
PREVALENCE OF AD
AD is the primary root cause of dementia; as of 2015, around 46.8 million people worldwide suffered from dementia 18 . This number is expected to increase exponentially to reach 131.5 million by 2050 if there are no interventions 18, 19 . In terms of prevalence between genders, AD is more of an old age disease, and women have been reported to have a longer life expectancy when compared to men 20 . Hence, women account for about two-thirds of the elderly population affected by AD. Indeed, AD has a direct economic burden worldwide, with studies indicating that AD management cost 818 billion USD in 2016; in 2018, the expected projected cost rose to 1 trillion USD 21, 22 .
AD CAUSATIVE HYPOTHESES TAU HYPOTHESIS
The tau hypothesis suggests that hyperphosphorylation of tau protein leads to the conversion of normal tau into the paired helical filament (PHF-tau) and NFTs [23] [24] [25] [26] [27] [28] [29] . Previously, Aβ had been the focus of AD research. Only recently have researchers begun to shift focus to tau protein due to the fact that a variety of reports have shown tau proteins being among the key elements contained in the NFTs. Tau protein, a member of the microtubule-associated protein, is also a functional monomeric and unfolded cell membrane protein, located within the cytosol of a neuron and very crucial in tubulin stabilization 30 . In addition, tau is known to control neurite growth and have a role in axonal guidance, thus enhancing the normal function of neurons 31 . In humans, tau protein is only found in trace levels in non-neuronal cells 32 . Tau goes through various post-translational changes, especially hyperphosphorylation, a process which acts as a significant factor in influencing the stability of microtubules, thereby leading to tau protein accumulation in AD 30 . Previous findings have shown that hyperphosphorylation of tau protein occurs via conformational changes, which are followed by the transformation of tau monomer to tau oligomer, leading to the paired helical filament and NFT formation [33] [34] [35] [36] [37] . Recent studies have revealed that NFT itself does not appear to be implicated in causing neurotoxicity leading to the onset of neurodegeneration 38 , though the hyperphosphorylated tau that disintegrates to form oligomers (the toxic form of tau) is implicated in neuronal damage 39 . In addition, recent in vivo and in vitro findings in rats have highlighted that tau pathology may have far-reaching effects in distinct brain regions [39] [40] [41] . Tau, a microtubule-associated protein, acts as a scaffolding component to assist in stabilizing microtubules by influencing tubulin stability in order to control the normal neuronal function 42, 43 . The position of the tau gene, microtubule-associated protein tau (MAPT), is essential and located on 100 kb of the long arm of human chromosome 17 at locus 17q21, and has 16 exons 44 . Moreover, it has been shown that in the brain of humans, the tau proteins encode six isoforms that have different sizes, with their length range being between 352 and 441 amino acids 45 . These isoforms have some variations, three repeats (3R) or four repeats (4R) in the C terminal, and also the presence or absence of one (29 amino acids) or two inserts (58 amino acids) in the Nterminal part, which bind to actin proteins and differentiate them. Findings have revealed that the repeat areas (244-268 amino acids) located in the C-terminal are the main domain, which causes the clinging of tau to microtubule 46, 47 . Furthermore, findings have suggested that tau phosphorylation at specific epitopes could adjust the capability of tau to cling to microtubule 48 . Many post-translational changes, mostly tau hyperphosphorylation, were considered to be involved as essential elements that influence the assembly of microtubule which, in turn, cause tau accumulation in AD 49 . Thus, tau protein goes through conformational alterations whereas the transformation of tau monomer to tau oligomer causes the accumulation of tau, thereby causing it to pair with a helical filament and produce NFTs (due to hyperphosphorylation of tau). Emerging studies have revealed that NFTs are not associated with causing neurotoxicity. Nonetheless, the intermediary tau oligomer was reported to be a toxic form of tau that is implicated in synaptic destruction in AD 50 . Tau pathophysiology is accompanied by abnormality of amyloid precursor protein (APP) and is eminently seen in the brain regions implicated in the memory-hippocampus as well as parts of the cerebral cortex 51 .
AMYLOID CASCADE HYPOTHESIS
Although the exact etiology of AD remains controversial, the amyloid cascade hypothesis has been widely accepted and is the most well-studied of the hypotheses out there 23 . The presence of amyloid plaques is, inarguably, a key characteristic of the pathology of AD. The amyloid cascade theory proposes that amyloid plaques, made by the accumulation of Aβ peptides which resulted from the proteolytic separation of APP, are crucial in AD pathology 52 . Studies have shown that the main composition of amyloid plaques in AD are polypeptides (about 4 kDa) that are usually produced in soluble form. Aβ protein has been shown to have a variety of isoforms, mostly ranging from 39 to 43 amino acids 52, 53 . The two isoforms of APP, APP751, and APP770 are made up of 56 amino acids in their ectodomain. Furthermore, findings have revealed that Aβ 1-40 (Aβ 40) and Aβ 1-42 (Aβ 42) are the two major occurring isoforms 54 . Abnormal processing of APP has been found to lead to the formation of disproportionate insoluble Aβ isoforms. These assemble and establish aggregates that consist of amyloid protein in the form of oligomers and protofibrils. Indeed, previous findings have suggested that this results from the changing of Aβ monomers to the Aβ oligomers before accumulation 55 . The oligomers eventually cause damage to the neurons 56 . Thus, high concentrations of indissoluble and likely Aβ 42 oligomers are involved in the synaptic elimination during early stage AD 57 .
Formation of Aβ
Aβ peptide 52,58 is a derivative of Amyloid βprecursor protein (Aβ PP), also an intrinsic type I glycoprotein 59 which has a broad ectodomain. The position of the chromosome for Aβ PP is found on 21q21.2. There are 18 exons in the APP gene that exceeds 170 kb, thereby creating 10 isoforms through discrete splicing. These isoforms measure between 563 and 770 amino acids. APP is 695 amino acids in length and is one of the isoforms that has been previously reported to be found in neurons of the central nervous system 60 . The specific area that codes Aβ -strings is made up of 16 and 17 exons, of which therein are (40 and 43) amino acid residues. Specifically, this area continues from the ectodomain to the protein's transmembrane domain 53 . APP's central domain possesses strong affinity; hence, it can bind to ions such as copper (Cu) and Zinc (Zn), as well as heparin and collagen, within the extracellular matrix, thereby mediating the interplay of APP with the extracellular matrix. The sphere implicated in the neuritic process is defined by a precise string which is seen following the inclusion of exon 7 product 61 . APP isoforms have been known to play vital roles in enhancing coordination between cells and, thus, a few of those roles are hereby outlined 62 . APP isoform (of 695 amino acid) has been shown to be involved in aiding coordination between cells and enhancing the connection to the extraneuronal matrix, thereby leading to stability. APP within the intracellular domain may be associated with a cytoskeletal system that transports constituents within a particular cell. APP1-671 (β APPs) and APP1-687 (αAPPs) are the other two APP isoforms produced in segments; they offer a protective role to the neurons and regulate events at the synapse 44 .
Processing of APP
Proteolytic series of events taking place around and in the APP transmembrane sphere yield a better expression for the production of toxic Aβ 42 protein, and eventually for AD pathogenesis. Three different divisions release the APP ectodomain from the membrane. These divisions have been confirmed to be α-secretase split (which separates Aβ -domain and inhibits Aβ -development-by generating amyloidogenic substance-due to the incapability of developing pathogenic Aβ ) 63 , β -secretase cleavage (the segment produced from α-secretase, while the β -secretase segments remains connected to the membrane; following further conversion by γ-secretase it becomes weakened), and Aβ -protein (Aβ 42) breakage (whose aggregation is thought to cause AD due to the presence of toxic and fibril aggregates) 52, 54, 58 .
Biochemistry of Senile Plaques
Blocq and Marnesco, in 1892, were the first to demonstrate that senile plaques (SP) could be described as densely packed structures called amyloid bodies. The process by which amyloid bodies develop and are implicated in AD development is known as amyloidosis. Fibrillogenic proteins (about 10 nm in diameter; amyloid fibrils that are smooth and straight) and non-fibril components (ApoE and serum Aβ components) are the contents of the amyloid bodies. The SPs, which are also called amyloid plaques, are the product of an extracellular accumulation of Aβ protein 60 .
CHOLINERGIC HYPOTHESIS
The oldest theory among the AD causative theories is the cholinergic hypothesis 64 . This hypothesis states that a decrease in neurotransmitters, known as acetylcholine, in neurons is responsible for AD etiology. The cholinergic hypothesis has been postulated for more than 3 decades now and suggests that abnormal acetylcholine-containing neurons in the basal ganglia are implicated in cognitive decline seen in AD patients 65 . Essentially, acetylcholine (ACh) is a neurotransmitter utilized by cholinergic neurons and is crucial for physiological processes like attention, learning, memory, stress response, wakefulness, and sleep, as well as sensory information [66] [67] [68] [69] [70] . Damage to cholinergic neurons was observed as an important pathological alteration which corresponds with cognitive destruction seen in AD. Consequently, this hypothesis was initially tested using cholinesterase inhibitors which are used for AD treatment. Thus, as a result of the trial, it has been noted that tacrine, one many cholinesterase inhibitors (including donepezil, galantamine, rivastigmine, and memantine), was the earliest anti-AD drug to be used in the clinic 71, 72 . However, due to some identified severe side effects, it has been retrieved from the market since 2012. Even though cholinesterase blockage is a typical palliative treatment with minor gain, presently, it appears to be the only obtainable clinical remedy that offers hope to despairing patients with AD. Despite these facts, the cholinergic hypothesis has not been widely accepted, mainly due to the fact that the medication was proposed to treat deficiency of acetylcholine but was not effective. Nonetheless, about 4 of the 5 approved anti-AD drugs available in the market today were developed based on the cholinergic hypothesis 23 .
OXIDATIVE STRESS HYPOTHESIS
Oxidative stress is believed to be critical in AD pathogenesis 73 . Notably, the brain is known to consume more energy and exert more functions than any other organs during mitochondrial respiration, which also increases the likelihood of reactive oxygen species (ROS) exposure 74 . Furthermore, AD is closely linked to molecular oxidative stress, as well as protein nitration, the rise of protein oxidation, lipid peroxidation, and glycoxidation. Moreover, AD is closely linked to the aggregation of Aβ , which has been reported to cause oxidative stress [75] [76] [77] [78] [79] [80] . Hence, antioxidant compounds are good candidates to offer protection against oxidative stress and Aβ toxicity, to a certain extent. Although oxidative stress is one aspect of AD, the antioxidant approach has been disputed, too, since it lacks the potential to impede the advancement of AD, and has been suggested to be used as part of combination therapy 81, 82 .
INFLAMMATION HYPOTHESIS
Recent studies have uncovered that neuroinflammation and aberrant gliosis are also emblems of AD 83 . Indeed, the inflammation hypothesis has been validated by genetic and transcriptomic studies [84] [85] [86] [87] . Microglia-related pathways were observed as crucial risk factors for AD and its pathogenesis. A wealth of information has indicated that microglia is a crucial factor. For instance, during the initial phase of AD, microglia and its associated proteins, such as the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2), can influence synaptic reduction 88, 89 . The process of activity-dependent and long-term synaptic plasticity is the typical and intrinsic molecular basis of learning and memory that could be the observable effects on long-term potentiation 90 . Thus, subsequently, amyloid plaques will be surrounded by aberrant microglia and astrocytes, and produce several proinflammatory cytokines. These series of events are the steps involved in the evolution of AD. However, in the clinic, non-steroidal anti-inflammatory drugs (NSAIDS) have not appeared to be beneficial. This could be largely due to the link between innate immunity and the complexity of AD pathogenesis; thus, the immune responses generated could either be detrimental or useful based on the context 87, 91, 92 . Nonetheless, there are new findings that indicate that the PD-1 immune crossing point barrier decreases the pathology of AD, thereby enhancing memory in AD mouse models [93] [94] [95] , and has become an area for subsequent research. The recent awareness towards uncovering the mechanisms involved regarding microglia disruption in clipping, neurogenesis and plasticity regulation are unlocking areas, allowing for the exploration of better therapeutic interventions and diagnoses of AD 96, 97 . Understanding the abnormal microglial roles and restoring homeostasis could provide a new set of concepts for treating AD. However, due to the intricacy and distinct roles of microglia in health and disease, new biomarkers that reflect the functions of specific microglia are critically needed 92, 98 . Despite all the above armamentarium, AD still needs to be properly understood in order to address its remote causes and the mechanisms underlying its progression, of which chemicals or drugs have been indicated as some of the causative factors.
MITOCHONDRIAL CASCADE HYPOTHESIS
Swerdlow was the first person to propose the mitochondrial cascade theory in 2004, where he posits that mitochondrial abnormality is the main reason for Aβ accumulation, the formation of NFT, and degeneration of synapses in AD 24 . Mitochondrial causative theory utilizes many theoretical liberties. It presumes that the physiologic mechanisms underlying AD and the aging brain are similar. It states that based on the fact that mitochondrial dysfunction in AD is systematic, mitochondrial dysfunction is not enough to represent the effects of neuronal degeneration. Furthermore, the hypothesis of the mitochondrial cascade forecasts that non-Mendelian inheritance is linked to non-autosomal dominant AD 23 . Lastly, it postulates that AD brain mitochondrial abnormality propels amyloidosis, phosphorylation of tau, and cell cycle re-entry. Mitochondrial dysfunction is detected in many AD tissues 25 , which include fibroblasts, platelets, mitochondria, and brain. There are three main defective mitochondrial enzymes involved: αketoglutarate dehydrogenase complex, pyruvate dehydrogenase, and cytochrome oxidase 26 . AD brain investigations have revealed a normal concentration of cytochrome oxidase but with an altered structure of the enzymes itself 27 . Oxidative stress and proteasome abnormality have been hypothesised to enhance mitochondrial dysfunction 28 . Moreover, studies involving cytoplasmic hybrids (cybrid) have revealed that mitochondrial DNA (mtDNA) is partly responsible for the decreased cytochrome oxidase in AD 29 .
COMMONLY USED CHEMICALS TO INDUCE AD-LIKE SYMPTOMS IN RODENTS
Some of the common chemicals used for modelling AD are scopolamine, streptozotocin, and alcohol, as well as dysregulation of heavy metals, such as aluminum (Al), copper (Cu), zinc (Zn), lead (Pb, and reducing sugar (D-galactose) 99 , among others ( Tables 1, 2 
and 3).

Aluminum as one of the frequently used heavy metals for induction of cognitive impairment
Environmental heavy metals are agents that have been well-established to impact the development of the brain through neurotoxicity 100 . Among the commonly used Alzheimerogenic chemicals, heavy metals have been identified to induce high levels of toxicity that is linked with several diseases, including neurodegenerative disorders, following long-term exposure in humans or chronic administration in rodents. A growing body of support has reported the relation between heavy metals and neurodegenerative diseases, including AD and Parkinson's disease 100 . Heavy metals are generally known to damage the nervous system. Of all the heavy metals, the effect of aluminum on biological systems has been well-reported 45, 101, 102 . Al is an ubiquitously scattered environmental and industrial toxicant associated with anemia 103 , osteomalacia, and hepatic and neurological disorders 103 . The high amount of Al has been identified in the brain of subjects suffering from AD and causes toxicological effects, including encephalopathy, bone disease, and anemia. Very recently, orally administered Al (300 mg/kg body weight) was reported to induce oxidative stress, cholinergic deficit, and accumulation of Aβ & NFTs in the brain of rats 101 . Moreover, in the Al-treated group, there are marked histopathological changes and diffuse gliosis accompanied by pericellular edema in the cerebral region, in addition to neuronophagia and loss of neurons. A number of studies have shown that Al neurotoxicity is highly linked with cognitive impairment of AD, via oxidative stress and cholinergic dysfunction 104 . The findings have indicated an upregulation in the expression and activity of acetylcholinesterase (AChE) and malondialdehyde (MDA), but a significant decrease in expression and activity of glutathione-s-transferase (GST), glutathione peroxides (GPX), and glutathione reductase (GR).
Scopolamine-induced AD-like dementia
A growing body of knowledge has established that scopolamine is an anticholinergic drug mostly employed as an approved chemical in pilot studies to cause memory deficit 105 . Administration of scopolamine leads to deficits in visual recognition memory, verbal recall, visuospatial praxis, visuospatial recall psychomotor speed, and visuoperceptual processes 106 . It is one of the most potent and commonly used drugs to prevent motion sickness 107 . Furthermore, researchers have documented that scopolamine non-selectively occludes the adhesion site of ACh muscarinic receptors in the cerebral cortex and results in the unequal discharge of ACh, which annihilates hippocampal neurons and induces learning and memory impairment in mice in a dose-related manner 108, 109 . However, the main effects of scopolamine likely result from blockage of some receptors (M1 and M5) due to their distinct distribution in the brain 110 . Previous studies have also suggested that it may lead to memory and learning deficit in a dose-dependent way 108, 109 . In some instances, ordinary doses of scopolamine led to agitation, confusion, hallucination, paranoid behaviors, delusions, and incoherent speech 111 . Previous studies have indicated there is potential participation of N-methyl-Daspartate (NMDA) receptor mechanisms of the dorsal hippocampus in memory loss due to scopolamine induction 112 . Currently, histone deacetylase-2 and DNA methyl transferase-1 are important for synaptic plasticity induced by scopolamine after a decrease in memory 113 . Hippocampal administration of scopolamine occludes long-term potentiation 114 and impedes spatial encoding 115 . Furthermore, the injection of scopolamine into the medial septum impedes learning and decreases ACh discharge into the hippocampus 116 , injection of scopolamine in the CA3 area of the hippocampus induces encoding impairments selectively, but memory retrieval in Hebb-William maze was not affected 117 .
Indeed, scopolamine has been identified to cause spatial learning and memory deficiencies. Consequently, it leads to the excitation of glycogen synthase kinase-3 beta (GSK-3β ), inadequate spine maturation, and the arborization of dendrites connected with alterations in CREC, Homer1, and amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA) 118 .
Colchicine-induced AD-like symptoms
Advances in chemicals used for modelling AD have suggested that colchicines are potential drugs that induce dementia through dysfunctional cholinergic neurons by either inhibiting cholinergic reversal or eroding cholinergic passage cascades 119, 120 . Colchicine induces hippocampal lesions resulting in cognitive impairments and ChAT reduction, suggesting that it can be utilized as a candidate for modelling AD. Colchicine could cause neurotoxicity and memory decline by inhibiting cholinergic pathways, thereby leading to a reduction in the number of cholinergic neurons and subsequently decreasing cholinergic renewal primarily within the hippocampal area of the brain 121 . Memory impairment seen induced by colchicine may be a result of a decrease in serotonin, dopamine, and norepinephrine within the caudate nucleus, hippocampus, and entire cerebral cortex 122 .
Furthermore, colchicine was shown to cause the production of protein carbonyls following lipid peroxidation 123 . Colchicine has also been found to raise cyclooxygenase-1, and 2 (COX-1 and COX-2) expression levels 124 and ROS generation 125 . Colchicine raises glutamate/GABA ratio in the cortex 126 and triggers excitation of MDA receptors that lead to a sharp rise in the influx of Ca 2+ , therefore resulting in the triggering of enzymes that depend on Ca 2+ (e.g. phospholipases A2, xanthine oxidase, proteases, cyclooxygenases, and protein kinases) 127 . Intracerebroventricular (ICV) administration of colchicine (7.5 g in 10 L) was found to recapitulate cognitive memory decline in rats 128 and similarly in mice 119 . A significant memory deficit was observed two weeks after cognitive induction impairment using colchicine 119 . Furthermore, 3 g/mice (ICV injection) of colchicine induces spatial memory impairment 129 . The main advantage of this model is the fact that it causes some symptoms of sporadic Alzheimer's type of dementia, similar to those found seen in human subjects, like time-variant changes in onset, behavioral, and biological patterns 123 .
Streptozotocin-induced AD-like cognitive decline
Streptozotocin (STZ), a compound derived from glucosamine nitrosourea and found in the strain of Streptomyces achromogenes, when administered ICV in rodents 130 , is known to exert a severe and long-lasting effect on the brain's cytoarchitecture, biochemistry, metabolism, and functions (such as decreased glucose uptake and energy consumption, oxidative tissue stress, cholinergic differential, and cognitive abilities). STZ is another alkylating agent used in cancer treatment. It has also been found to mimic certain properties of nitrosourea, an anti-cancer agent that has been reported to have hypoglycemic effects in addition to being involved in memory damage 110 . Induction of neuronal damage and hyperphosphorylation of tau is caused by STZ, resulting in the release of ROS and reactive nitrogen species (RNS) 131 . Findings revealed that STZ destructs the glycolytic enzyme activity within the brain which eventually results in the lowering of ATP and creatine phosphate concentrations. This destructed energy system and lowered acetyl CoA synthesis can inhibit cholinergic conductance 130 . Rats induced by STZ have been reported to demonstrate raised activities of AChE in their brains and decreased ACh. In other studies, STZ has been found to activate Aβ peptide-like aggregates by modifying the GSK alpha/beta 132 . Furthermore, there is evidence that gene expression associated with the development of glial-derived NF, brain-derived neurotrophic factors (BDNF) and integrin -alpha-M becomes increased by STZ, while expression of genes for NGE-IB and metallothionein 1/2 is down-regulated and eventually results in the modification in apoptosis and cell survival process 133 . Administration of ICV-STZ resulted in a substantial decrease in memory and learning skills of rats, leading to oxidative stress 134 . Additionally, ICV administration of STZ (3 mg/kg) in a model of cognitive impairment in rats mimicked the sporadic dementia of AD 135 . Memory impairment was observed in the rats during the last phase of the experiment using the Morris water maze (MWM) task in order to assess AD-like symptoms. In addition, impaired glucose metabolism, a decrease in cholinergic markers, and oxidative stress were seen in the rats' brains. Altogether, these long-lasting effects mimicked those seen in AD patients. 
Ethanol/Alcohol induced AD-like symptoms
Chronic intake of alcohol is associated with many problems including attention deficits, impairment in language and social skills, hyperactivity, motor dysfunction, and learning deficits 171 . Previous studies have shown that ethanol consumption enhances the generation of ROS and results in a decrease of the antioxidants in the brain 172 . Another finding has suggested that ethanol could damage hippocampal and cholinergic neurons with a resultant effect on the sensory-motor system as well as disruption of learning and memory 173 . High ethanol treatment resulted in excessive nitric oxide (NO), which has been found to destruct memory and learning, while higher doses of ethanol disrupted the glutamatergic system and increased GABAergic conveyance in the brain areas that are associated with memory 173 . Ethanol also elevates the level of adenosine, which may, in turn, lead to memory damage 174 and can result in a shorter route by accelerating memory impairment and promoting active, spontaneous motion. Furthermore, results obtained following the MWM test in mice showed a notable increase in escape latency and total swimming distance, with a sharp drop in cross time. Thus, chronic alcohol administration can significantly affect spatial learning ability and cognition by mice 175 . However, memory impairment caused by prolonged alcohol intake can be observed from the anti-inflammatory activity and from the control of the equilibrium of Glu and GABA 176 .
The particular molecular mechanisms still need further investigations, but overall, alcohol can significantly disrupt learning and memory.
Memory deficit induced by excitotoxin
Ibotenic acid is a strong neurotoxin that aggravates signs and pathophysiology analogous to AD 177, 178 .
It is a useful model to appreciate drug efficiency in evading AD pathology. It has also been found that intrahippocampal administration of ibotenic acid (5 µg/µl PBS) produces memory impairment and results in increased AChE activity as well as elevated MDA levels, thereby inducing neuronal toxicity 179 . Bilateral ICV injection of ibotenic acid may elicit AD-like pathology and symptoms. Indeed, a particular study found that ibotenic acid decreased the activity of cholinergic neurons in rats 180 . Many other cholinotoxins and neurotoxins that present AD-like symptoms are kainic acid, quinolinic acid, anti-NGF, NMDA antagonist dizocilpine, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). Previous studies have reported that intrahippocampal kainic acid (0.4 µg/2µl) administration led to oxidative damage (revealed by the increase of hippocampal lipid peroxidation, nitrite level, and diminished superoxide dismutase (SOD)). Thus, it is clear that kainic acid activates oxidative damage and memory loss in rats 181 . Stimulation of glutamate receptors, particularly NMDA receptors, in a diseased condition can lead to disrupted ion homeostasis, decrease in energy, neuronal loss, and cell death (excitotoxicity) by an abnormally high concentration of glutamate 182, 183 .
Sodium azide-induced AD-like memory impairment
Sodium azide (NaN3) is a white crystalline solid that has been reported to be a mitochondrial toxin implicated in the production of lead azide explosive 184 . NaN3 administration has been known to induce mitochondrial dysfunction and inhibit cytochrome oxidase, a critical mitochondrial enzyme 169 . Cytochrome oxidase is critical in the mitochondrial respiratory chain; its interference impedes with mitochondrial complex-IV and decreases ATP levels, which add to metabolic impairment and ROS generation 170 , ultimately producing some sequelae of AD. Neuronal loss in the CA3 area of the hippocampus is one of the essential features used to confirm the induction of AD using minipumps to deliver NaN 3 . However, due to high cost, one-time usability and long treatment time, minipumps are unlikely to be useful tools for screening. A new technique was developed to provide an AD-like dementia model by selective cytochrome C complex inhibition using an intraperitoneal injection of NaN 3 in different doses (10-15 mg/kg/day) in rats. The intraperitoneal injection dose-effect-interdependence study employed mitochondrial poison and developed a complex test system to research changes in cognitive functions induced by treatment with NaN 3 . It has been shown that NaN 3 administration impairs learning and memory, and increases AChE levels in the brain 169 . NaN 3 was reported to cause oxidative damage that resulted in neuronal cell death. The progressive loss of neurons and necrosis were observed in the cortical and hippocampal areas of treated rats, thereby further indicating the potency of NaN 3 . These researchers confirmed that intraperitoneal injection of NaN 3 for 15 days resulted in a comparable level of dementia using implanted osmotic minipumps in rats, ultimately suggesting the involvement of NaN 3 in inducing neurodegenerative disorder 185 . A growing body of knowledge has reported that oxidative stress (Figure 1) is a trigger, as well as one of the critical molecular changes for AD commencement 186 . Oxidative stress may be caused by inhibition of mitochondrial function. The mitochondrial enzyme, Cytochrome oxidase (COX), has long been established to be predominantly implicated in aerobic energy metabolism and mitochondrial tasks in AD patients 187 . Brains of AD patients have shown some mitochondrial abnormalities, particularly of CoX type. The primary toxic effect of NaN 3 has been identified as decreasing the action of CoX in the mitochondrial electron transport chain 185 .
LPS-induced AD-like symptoms
LPS has been known to be used in various experiments, both in vitro and in vivo models of amyloidosis and neuroinflammation 188, 189 . A variety of neurodegenerative diseases, namely AD 189 , Parkinson's disease 190 , amyotrophic lateral sclerosis 191 , and multiple sclerosis 192 , have been modeled using LPSinduced systemic inflammation (Figure 2) . LPS is extracted from the external membrane of gram-negative bacteria. It has been reported as a strong endotoxin with resistivity to degradation by mammalian enzymes, therefore resulting in continual inflammatory stimuli 193 , which produce proinflammatory cytokines. These proinflammatory cytokines stimulate both neuroimmune and neuroendocrine systems 194 that lead to virtually similar feedback formed by behavioral stress 195 . Inflammation has been reported to be crucial in AD pathogenesis. However, the exact mechanisms through which it participates remains to be elucidated. Inflammatory proteins in the blood, two of which are C reactive protein (CRP) and IL6, have been reported to increase several years before the onset of clinical dementia in different studies 12, 196 . Inflammation is one of the factors that cause AD, although the link between infections and AD etiology has been an issue of debate for more than three decades 197 . Previous studies have indicated that the expression levels of TNF-α, IL-1β , and IL-6 within the hippocampus are upregulated in comparison with those of control following three days of LPS administration 198 . Proinflammatory cytokines have already been found as the critical molecules which modulate immune responses; inability to reverse them during chronic inflammation would increase dyshomeostasis 198 . Moreover, long-standing microglia activation which facilitates inflammatory mediators release, resulting in enhanced oxidative stress and nitrosative stress, is characterized by chronic inflammation 199 .
Okadaic acid-induced memory impairment
Okadaic acid (OKA), a major polyether toxin, is a marine microalgae product that causes diarrhetic shellfish toxicity 200 . IC injection of OKA has been reported to induce memory decline in rats, therefore making it a valuable model agent to study for antidementia drug screening 201 . In terms of mechanism of action, OKA has been found to be a restrictive and modest antagonist of serine/threonine phosphatases 1 and 2A 202, 203 , is associated with short-and longterm memory disruption in rats 204 , and triggers tau hyperphosphorylation (Figure 2) and neuronal cell death both in vivo 205 and in vitro 206 . Previous findings have identified that OKA decreases basal synaptic transmission and inhibits the commencement of synaptic plasticity 207 . Also, OKA has been found to augment Ca 2+ in a cultured hippocampal neuronal cells by ionotropic excitatory amino acid receptors, thereby leading to loss of neurons 208 . Furthermore, research has demonstrated that OKA triggers the production of ROS in the hippocampus and reduces mitochondrial activity and mitochondrial potency, ultimately resulting in mitochondrial abnormalities in the brain of rats 201 . Additionally, OKA has been known to inhibit phosphatases and cause hyperphosphorylation of proteins which subsequently leads to neuronal stress and ultimately to neurodegeneration 201 . Previous findings revealed that OKA-mediated memory decline in rats is linked with exacerbated proinflammatory cytokines, such as TNF-α and IL-1, and with iNOS expression and total nitrite in the hippocampus and cortex 209 . Furthermore, infusion (bilateral) of OKA in the hippocampus produced spatial cognitive deficit as a result of raised GFAP expression, decreased GSH, and enhanced protein carbonylation and mitogen-activated protein kinase 38 (p38MAPK) 210 . Several kinases, including MAPK, GSK-3β and cyclin-dependent kinase 5 (Cdk5), have been identified to be implicated in the phosphorylation of tau protein at different positions seen in AD hyper-phosphorylated tau 211, 212 . Meanwhile, tau dephosphorylation is catalyzed through phosphatase PP2A and other phosphatases (PP1, 2B, and 5) 213, 214 . The precise blocking of PP2A by OKA could result in Alzheimer-like hyperphosphorylation and aggregation of tau in vivo 215 and in vitro 216, 217 . Memory loss due to OKA (intra-hippocampal) injection has been documented to be linked with apparent neuropathological changes, such as the formation of Aβ peptide-like structures, helical filamentlike phosphorylated tau, and neurodegeneration in the hippocampus 210 . OKA is an essential means for Figure 2 : Alzheimerogenic chemicals and some mechanisms used to induce AD. The figure showed some insults underlying AD, the chemicals here induced AD-like cognitive impairments due to the individual mechanism of action. Chronic or acute exposure to any of these chemicals by the brain is associated with one or more of the pathophysiology contained in the box (dotted line). Adapted from Lee et al., 2018 188 . analyzing 218 the cellular mechanisms involved by reversible protein phosphorylation during cell division, signal transduction, and formation of memory 217 . At present, drugs that act by blocking tau phosphorylation are not available. Thus, this suggests that OKA could be a useful replacement tool towards unravelling therapeutic approaches for AD pathology 198 .
CONCLUSION
Several chemicals have been established in order to unravel AD etiology and screen many possible therapeutic agents. This applies especially to aging, Aβ , aluminum, and D-galactose models, among others. Nonetheless, it is worthy to note that none of the available models recapitulates the exact pathology of AD, although every model is known to have its benefits and triggers a few of the pathophysiology linked with AD. Heavy metals, scopolamine, alcohol, and LPS are among the chemicals with proven neurotoxicity and have been used to induce AD-like cognitive impairment in rodents. Each chemical may act via specific mechanisms that differ in order to exacerbate AD pathogenesis. Thus, the dosage, as well as the time in which the chemical is administered in the AD models of rodents, may be higher or sometimes lesser to induce severe disease in human subjects. Importantly, other factors associated with the Alzheimerogenic chemicals are the route of administration, nature, duration (especially), as well as age and gender of the animals tested. This understanding is critical in order to design research that involves chemicallyinduced cognitive impairment. 
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